Author/Authors :
YILMAZ, Ömer Süleyman Demirel University - Faculty of Medicine - Department of Radiology, Turkey , UGAN, Yunus Süleyman Demirel University - Faculty of Medicine - Department of Rheumatology, Turkey , YENER, Mahmut Süleyman Demirel University - Faculty of Medicine - Department of Physical Therapy and Rehabilitation, Turkey , UMUL, Mehmet , KAYAN, Mustafa Süleyman Demirel University - Faculty of Medicine - Department of Radiology, Turkey , AKTAŞ, Aykut Recep Süleyman Demirel University - Faculty of Medicine - Department of Radiology, Turkey , ÜNLÜ, Elif Nisa Süleyman Demirel University - Faculty of Medicine - Department of Radiology, Turkey , KISACIK, Bünyamin Gaziantep University - Faculty of Medicine - Department of Rheumatology, Turkey , DEĞİRMENCİ, Bumin Süleyman Demirel University - Faculty of Medicine - Department of Radiology, Turkey , ÇETİN, Meltem Süleyman Demirel University - Faculty of Medicine - Department of Radiology, Turkey
Abstract :
Aim: To evaluate the effects of anti-tumor necrosis factor-alpha (TNF-α) therapy on the frequency of varicocele in patients with ankylosing spondylitis (AS) using color Doppler ultrasound. Materials and methods: The patients were divided into 2 groups: patients with AS who were on anti-TNF-α treatment and patients with AS who were not regularly taking any antiinflammatory drugs. Thirty-one healthy volunteers were included as controls. Results: Left-sided varicocele was determined in 14 patients of Group 1 (44%), 10 patients of Group 2 (33%), and 7 of the controls (23%). There was a statistically significant difference only between Group 1 and controls (P = 0.009). However, right-sided varicocele was determined in 12 patients of Group 1 (38%), 2 patients of Group 2 (6%), and 2 of the controls (6%) (P = 0.01 vs. Group 2, P = 0.005 vs. controls). Conclusion: The present study shows that patients with AS who were taking anti-TNF-α therapy had an increased prevalence of rightsided and bilateral varicocele compared to patients with AS who were not taking any disease-modifying antirheumatic drugs and the healthy control group.
